J Gastric Cancer.  2014 Mar;14(1):39-46.

Can Perioperative Chemotherapy for Advanced Gastric Cancer Be Recommended on the Basis of Current Research? A Critical Analysis

• Bauer K
• Porzsolt F
• Henne-Bruns D

Abstract

PURPOSE
According to current guidelines, perioperative chemotherapy is an integral part of the treatment strategy for advanced gastric cancer. Randomized controlled studies have been conducted in order to determine whether perioperative chemotherapy leads to improved R0 resection rates, fewer recurrences, and prolonged survival. The aim of our project was to critically appraise three major studies to establish whether perioperative chemotherapy for advanced, potentially resectable gastric cancer can be recommended on the basis of their findings.
MATERIALS AND METHODS
We analyzed the validity of the three most important studies (MAGIC, ACCORD, and EORTC) using a standardized questionnaire. Each study was evaluated for the study design, patient selection, randomization, changes in protocol, participating clinics, preoperative staging, chemotherapy, homogeneity of subjects, surgical quality, analysis of the results, and recruitment period.
RESULTS
All three studies had serious shortcomings with respect to patient selection, homogeneity of subjects, changes in protocol, surgical quality, and analysis of the results. The protocols of the MAGIC and ACCORD-studies were changed during the study period because of insufficient recruitment, such that carcinomas of the lower esophagus and the stomach were examined collectively. In neither the MAGIC study nor the ACCORD study did patients undergo adequate lymphadenectomy, and only about half of the patients in the chemotherapy group could undergo the treatment specified in the protocol. The EORTC study had insufficient statistical power.
CONCLUSIONS
We concluded that none of the three studies was sufficiently robust to justify an unrestrained recommendation for perioperative chemotherapy in cases of advanced gastric cancer.

Keyword

Perioperative chemotherapy; Lower esophageal cancer; Stomach neoplasms; Cancer of the esophagogastric junction

MeSH Terms

Drug Therapy*
Esophagus
Humans
Lymph Node Excision
Magic
Patient Selection
Random Allocation
Recurrence
Stomach
Stomach Neoplasms*
Surveys and Questionnaires

Reference

1. World Cancer Research Fund International. Cancer frequency by country, Source: GLOBOCAN 2008 database (version 1.2) [Internet]. London: World Cancer Research Fund International;2008. updated 2014 Feb 14. Available from: www.wcrf.org.

2. Robert-Koch-Institut. Cancer in Germany, friquencies and trends.222.rki/krebs.de [Internet]. Berlin: Robert-Koch-Institut;2010. updated 2013 Dec 13. Available from: http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Magenkrebs/magenkrebs_node.html.

3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8:784–796.

4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010; 303:1729–1737.

5. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002; 168:597–608.

6. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, et al. German S3-guideline "Diagnosis and treatment of esophagogastric cancer". Z Gastroenterol. 2011; 49:461–531.

7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11–20.

8. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010; 28:5210–5218.

9. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29:1715–1721.

10. Porzsolt F, Braubach P, Flurschütz PI, Göller A, Sailer MB, Weiss M, et al. Medical students can help avoid the expert bias in medicine. Creat Educ. 2012; 3:1115–1121.

11. Bauer K, Porzsolt F, Henne-Bruns D. Validity of the MAGIC study: sufficient for recommendations? Hepatogastroenterology. 2013; 60:1822–1824.

12. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974; 15:443–453.

13. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975; 31:103–115.

14. Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials. a review. Control Clin Trials. 2002; 23:662–674.

15. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004; 30:643–649.

16. Wittekind C, Bertolini J. TNM-system 2010. Onkol. 2010; 16:175–180.

17. Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010; 116:3763–3773.

18. Power DG, Schattner MA, Gerdes H, Brenner B, Markowitz AJ, Capanu M, et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg. 2009; 208:173–178.

19. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64:31–49.

20. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11:439–449.

21. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000; 21:167–189.

22. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985; 312:1604–1608.